Sector News

ThromboGenics strengthens leadership team

November 8, 2017
Life sciences

ThromboGenics NV, a biotechnology company developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team with the appointment of Susan Schneider, MD, as Chief Medical Officer, and Vinciane Vangeersdaele as Chief Commercial Officer.

Both will be members of the Company’s executive team reporting to ThromboGenics’ CEO, and they will operate from the Company’s offices in Leuven, Belgium and Iselin, New Jersey, US.

Susan Schneider, MD, brings nearly 15 years of experience in clinical drug development to ThromboGenics. Prior to joining ThromboGenics, she was, most recently, Vice President & Therapeutic Area Head of Retina & Glaucoma at Allergan. Susan received her medical degree from the Medical College of Pennsylvania followed by a residency in ophthalmology at the Medical College of Virginia. At ThromboGenics, Dr. Schneider will be responsible for the development and execution of the Company’s global clinical and medical programs that are focused on its industry-leading pipeline of drug candidates targeting diabetic eye disease.

Vinciane Vangeersdaele has recently joined ThromboGenics as Chief Commercial Officer. Vinciane has over 15 years of experience in a variety of sales and marketing leadership roles in the global pharmaceutical industry, the latest being the Head of the Ophthalmology Franchise Europe  at Novartis AG. She obtained a master degree in business engineering at the University of Mons-Hainaut. At ThromboGenics, Vinciane will be leading and developing the overall commercial strategy for the Company’s recently formed global JETREA business unit, which was created following ThromboGenics regaining the full global rights to JETREA® from Novartis. She will also be leading the strategic marketing activities for any new compound that emerges from the Company’s clinical development pipeline, which is focused on diabetic eye disease.

Patrik De Haes, MD ThromboGenics CEO, comments: “We are very pleased to welcome Susan and Vinciane to ThromboGenics. I am convinced that their extensive experience will be crucial as we simultaneously progress our pipeline of novel drug candidates targeting diabetic eye disease and develop our commercial plans for JETREA® beyond the US following our recent agreement with Novartis. With our current significant cash resources, a strong clinical pipeline and a first class executive team we are well placed to deliver shareholder value.”

Source: ThromboGenics

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).